Stryker Co. (NYSE:SYK) Shares Purchased by Summit Trail Advisors LLC

Summit Trail Advisors LLC boosted its holdings in Stryker Co. (NYSE:SYK) by 8.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,494 shares of the medical technology company’s stock after acquiring an additional 441 shares during the quarter. Summit Trail Advisors LLC’s holdings in Stryker were worth $1,989,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Centennial Bank AR increased its position in shares of Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 48 shares during the period. Darwin Wealth Management LLC acquired a new stake in Stryker during the third quarter valued at $36,000. HBW Advisory Services LLC acquired a new stake in Stryker during the third quarter valued at $42,000. Hara Capital LLC acquired a new stake in Stryker during the third quarter valued at $42,000. Finally, Grove Bank & Trust lifted its position in shares of Stryker by 84.8% in the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after buying an additional 56 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP M Kathryn Fink sold 2,121 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00. Following the completion of the sale, the vice president now owns 10,042 shares of the company’s stock, valued at $3,715,540. This represents a 17.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Viju Menon sold 600 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares of the company’s stock, valued at $3,219,495. This trade represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 67,381 shares of company stock worth $24,825,275. Insiders own 5.50% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $384.85 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker Co. has a twelve month low of $285.79 and a twelve month high of $398.20. The firm’s 50 day moving average price is $366.20 and its two-hundred day moving average price is $349.63. The firm has a market cap of $146.71 billion, a P/E ratio of 41.25, a PEG ratio of 2.90 and a beta of 0.91.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.46 earnings per share. On average, analysts forecast that Stryker Co. will post 12.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their target price on Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Wolfe Research started coverage on shares of Stryker in a report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 price objective on the stock. Citigroup increased their target price on shares of Stryker from $406.00 to $411.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. BTIG Research boosted their price target on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, Royal Bank of Canada raised their price objective on Stryker from $386.00 to $400.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $393.65.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.